IFIH1 and cancer: Among 72 IIM patients with malignancies in a cohort study from Northern China, 38 tested positive for anti-TIF1-γ, 3 for anti-NXP2, 4 for anti-SAE1, 10 for anti-ARS, 1 each for anti-MDA5, anti-HMGCR, and anti-SRP (23).